

Seydel et al.			[45] Date of Patent: Mar. 27, 1990
[54]	THEIR PE	UTED INO-5-BENZYLPYRIMIDINES, REPARATION AND THEIR USE AS MENTS WITH AN ROBIAL ACTIVITY	[58] Field of Search
[75]	Inventors:	Joachim Seydel, Borstel; Rolf Haller; Manfred Kansy, both of Kiel; Gerd Hachtel, Raisdorf, all of Fed. Rep. of Germany	4,143,227 3/1979 Rosen
[73]	Assignee:	Saarstickstoff-Fatol GmbH ChemPharm. Fabrik, Schiffweiler, Fed. Rep. of Germany	[57] ABSTRACT Novel substituted 2,4-diamino-5-benzyl pyrimidines are described. The novel substances have antimicrobia
[21]	Appl. No.:	11,957	activity and are particularly suitable for inhibiting the growth of mycobacteria. Combined with inhibitors such as diaminodiphenylsulphones, ring-substituted
[22]	Filed:	Feb. 6, 1987	
[30] Fe	Feb. 6, 1986 [DE] Fed. Rep. of Germany 3603577		4-aminodiphenylsulphones or ring and/or nitrogen-sub- stituted diaminodiphenylsulphones, they have a marked synergistic activity.
[51] [52]	<u> </u>		21 Claims, 2 Drawing Sheets

United States Patent [19]

[11] Patent Number:





I

SUBSTITUTED 2,4-DIAMINO-5-BENZYLPYRIMIDINES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS WITH AN ANTIMICROBIAL **ACTIVITY**

The invention relates to novel substituted 2,4diamino-5-benzylpyrimidines, their preparation and their use as medicaments for the treatment of microbial 10 and in particular mycobacterial infections.

The antibacterial activity of compounds of the benzylpyrimidinetype is known. Such compounds, such as e.g. the known products trimethoprim, brodimoprim and tetroxoprim exert their activity by inhibiting dihydrofolic acid reductase (DHFR) in the case or Gram negative and Gram positive bacteria. However, it has been found that these compounds have only an extremely limited activity with respect to mycobacteria. With these agents the concentrations necessary for in- 20 hibiting mycobacterial growth are so high, that they cannot be attained in vivo or are not acceptable.

The problem of the present invention is therefore to provide compounds, which in low physiologically acceptable concentrations constitute effective inhibitors 25 of microbial growth and particularly mycobacterial growth.

According to the invention this problem is solved by the novel substituted 2,4-diamino-5-benzylpyrimidines of general formula I

$$\begin{array}{c|c} & NH_2 \\ & & \\ N & & \\ & & \\ H_2N & & \\$$

in which one of the substituents R1 to R3

carbon atoms and advantageously 4 to 10 carbon atoms, a phenylalkoxy, phenylalkylthio, phenoxyalkoxy, phenoxyalkylthio, phenylaminoalkoxy, phenylaminoalkylthio group with 3 to 6 C atoms in the alkyl chain or a, cycloalkoxy, cycloalkylthio, cycloalkylalkylthio or 45 cycloalkylalkoxy group wherein the cyclic radical as well as the alkyl chain have 3 to 6 carbon atoms respectively or

(ii) a 2',4'-substituted phenyl-4-sulphonylphenyl aminoalkoxy, phenyl-4-sulphonylphenyl-aminoalkylthio, 50 phenyl-4-sulphonylphenylalkoxy or phenyl-4-sulphonylphenylakylthio group, in which the substituents in the 2',4'-position are the same or different and are hydrogen, amino, alkylamino, dialkylamino, alkoxy, alkyl, nitro, alkylthio and/or acetamino groups wherein 55 the alkyl radical has 1 to 6 C-atoms in the chain and the two others of the substituents R1 to R3 are the same or different and are hydrogen, alkoxy, alkylthio and/or alkylamino groups.

The alkyl radical of the two other substituents R1 to 60 kylthio or cycloalkylalkoxy group, R³ preferably has 1 to 3 C-atoms and in particular 1 C-atom.

Representative examples of compounds of the invention include 2,4-diamino-5-(4-propoxyphenyl-benzyl)pyrimidine; 2,4-diamino-5-(4-propoxyphenyl-3-65 methoxy-benzyl)-pyrimidine; 2,4-diamino-5-(4-pentloxy-3-methoxybenzyl)-pyrimidine; 2,4-diamino-5-(4hexyloxy-3-methoxybenzyl)-pyrimidine; 2,4-diamino-5-

(4-heptyloxy-3-methoxybenzyl)-pyrimidine; 2.4diamino-5-(4-octyloxy-3,5-dimethoxybenzyl)-pyrimidine; 2,4-diamino-5-(4-nonyloxy-3,5-dimethoxybenzyl)pyrimidine; 2,4-diamino-5-(4-decyloxy-3-methoxybenzyl)-pyrimidine; 2,4-diamino-5-[3,5-dimethoxy-4-(4'nitrophenyl-4-sulphonylphenyl)-methoxybenzyl]pyrimidine; 2,4-diamino-5-(3,5-dimethoxy-4-[3-(4'nitrophenyl-4-sulphonylphenylamino)propoxy]benzyl)-2,4-diamino-5-(4-methoxy-3-[2-(4'pyrimidine; nitrophenyl-4-sulphonylphenylamino)ethoxy]benzyl)-2,4-diamino-5-(4-methoxy-3-[3-(4'pyrimidine; nitrophenyl-4sulphonylphenylamino)propoxy]benzyl)-2,4-diamino-5[4-(4'-aminophenyl-4-sulpyrimidine; phonylphenylmethoxy)-3,5-dimethoxybenzyll-pyrimidine; 2,4-diamino-5-(4-[3-(4'-aminophenyl-4-sulphonylphenylamino)-propoxy]-3,5-dimethoxybenzyl)-pyrimi-2,4-diamino-5-[3-(4'-aminophenyl-4-sulphonylphenylmethoxy)-4-methoxybenzyl] -pyrimidine; 2,4diamino-5-(3-[2-(4'-aminophenyl-4-sulphonylphenylamino)-ethoxy]-4-methoxybenzyl)-pyrimidine; 2,4-diamino-5-(4-[3-(4-aminophenyl-4-sulphonylphenylamino)propoxy]-3,5-dimethoxybenzyl)-pyrimi-2,4-diamino-5-(4'-aminophenyl-4-sulphonylphenylmethoxy)-3-methoxybenzyl]pyrimidine; diamino-5-(4-[3-(4'-methylphenyl-4-sulphonylphenylamino) -propoxy]-3,5-dimethoxybenzyl)-pyrimidine; 2,4-diamino-5-(4-[2-(4'-aminophenyl-4-sulphonylphenylamino)ethoxy]-3,5-dimethoxybenzyl)-pyrimidine; 2,4-diamino-5-(4-[2-(2'-methyl-4'-aminophenyl-4sulphonylphenylamino)ethoxy)-3,5-dimethoxybenzyl)pyrimidine.

According to the invention, it has surprisingly been found that the introduction of substituents according to formula I into compound of the benzylpyrimidine type leads to a dramatic increase in the activity of these compounds as mycobacterial growth inhibitors (cf. table 1).

The inventive substituted 2,4-diamino-5-benzyl-(i) is an alkoxy or alkylthio group with more than 4 40 pyrimidines can be prepared in that for obtaining compounds according to formula I (i)

(aa) a compound of general formula II

in which one or the substituents R¹ to R³ is a hydroxyl or a mercapto group and the two other of the substituents R¹ to R³ are the same or different and are hydrogen, alkoxy, alkylthio and/or alkylamino groups is etherified with a halide suitable for forming an alkoxy, alkylthio, phenylalkoxy, phenylalkylthio, phenylalkoxy, phenoxyalkylthio, phenylaminoalkoxy, phenylaminoalkylthio, cycloalkoxy, cycloalkylthio, cycloalkylal-

(ab) the compound obtained in stage aa) is condensed with a β -morpholinopropionitrile,

(ac) the compound obtained in stage ab) is reacted with aniline and

(ad) the compound obtained in stage ac) is cyclized with guanidine.

For the preparation of compounds according to formula I (ii) it is possible to either

· III

$$\begin{array}{c}
N \\
N \\
N
\end{array}$$

$$\begin{array}{c}
CH_2 \\
R^2
\end{array}$$

$$\begin{array}{c}
R^1 \\
R^2
\end{array}$$

in which one of the substituents R1 to R3 is a hydroxyl or a mercapto group and the two other of the substituents R1 to R3 are the same or different and are hydrogen, alkoxy, alkylthio and/or alkylamino groups is etherified with a compound of general formula IV

$$R^4$$
— $(CH_2)_n$ — R^6
 R^6
 R^6
 R^6
 R^6
 R^6
 R^6
 R^6

or formula V

in which R4 is a halogen radical and R5 and R6 are the same or different and are hydrogen, amino, alkylamino, dialkylamino, alkoxy, alkyl, nitro, alkylthio and/or acetamino groups.

Etherification appropriately takes place in per se known manner in solvents such a water, methanol, ethanol, n-propanol, isoproaanol, butanol, dimethylformamide, dimethylsulphoxide, acetone, methylethylketone and monoalkylated and dialkylated ethers of ethyleneglycol and diethyleneglycol and mixtures thereof, accompanied by the addition or a base such as sodium, sodium ethoxide, sodium or potassium hydroxide, potassium or sodium carbonate at a temperature between -20° C. and the boiling point of the solvent $_{45}$ used, but preferably at ambient temperature.

According to a preferred embodiment of the invention, etherification is carried out in ethyleneglycol monomethylether as the solvent and the sodium alkoxide of the ethyleneglycol monomethylether.

be prepared in that

(bb) a compound of general formula VI

$$\begin{array}{c} N \\ N \\ N \\ N \end{array} \begin{array}{c} CH_2 \\ R^2 \end{array} \qquad VI$$

is reduced, in which one of the substituents R1 to R3 is a 2',4' substituted phenyl-4-sulphonylphenylaminoalkoxy, phenyl-4-sulphonylphenylaminoalkylthio, phenyl-4-sulphonylphenylalkoxy or phenyl-4-sulphonylalkylthio group with a terminal nitro group, the substitu- 65 ents in the 2 '4'-position being the same or different and hydrogen, amino, alkylamino, dialkylamino, alkoxy, alkyl, nitro, alkylthio and/or acetamino groups and the

two other of the substituents R¹ to R³ are the same or different and are hydrogen, alkoxy, alkylthio and/or alkylamino groups.

Reduction is appropriately carried out in per se known manner in solvents such as water, methanol, ethanol, glacialacetic acid, ethylacetate, dimethylformamide, water/ethanol, water/dioxan, water tetrahydrofuran, ethyleneglycol monomethylester and further alkyl and aryl ethers of ethylene glycol, diethyleneglycol and mixtures thereof in the presence of a hydrogenating catalyst such as Raney nickel, platinum or palladium/charcoal. Reduction can take place with metals such as iron, tin or zinc in the presence of an acid such as hydrochloric or acetic acid, with salts such as ferrous sulphate, stannous chloride/hydrochloric acid or sodium dithionide in the presence of a base such as sodium hydroxide solution, pyridine or hydrazine and Raney nickel, the temperatures being between 0° and 100° C., but preferably 50° C.

It has proved to be particularly advantageous to carry out the reduction in ethyleneglycol monomethylether, methanol or mixtures thereof at 50° C, 1 to 6 bar and in the presence of Raney nickel W2 (produced in accordance with Org. Synth. Coll. 3, 181, 1955) or palladium/charcoal.

The effectiveness of the compounds according to the invention as growth inhibitors for in particular mycobacteria was proved on bacterial cell cultures by determining the minimum inhibiting concentrations and the concentrations necessary for half maximum growth inhibition (I₅₀) when using typical representatives of the inventive compounds.

There was surprisingly found to be an up to 300 times increased activity of the inventive compounds compared with commercially available products, such as e.g. pyrimethamine. There was also found to be a synergistic effect of combinations of the claimed compounds and inhibitors of dihydropteroic acid synthetase, such as e.g. with diaminodiphenylsulphone (DDS).

The inventive compounds can therefore be used as active ingredients in medicaments for the treatment of microbial infections and in particular mycobacterioses either alone or combined with inhibitors such as ring-substituted diaminodiphenylsulphones, aminodiphenylsulphones or ring and/or nitrogen-substituted diaminodiphenylsulphones and/or antibacterially acting sulphonamides. Their importance lies inter alia in the possibility of treating both partially DDS and The compounds according to formula I (ii) can also

TMP-resistant mycobacterioses and avoiding the development of resistance in the case of DDS or TMP monotherapy.

The inventive medicaments contain the active substances of the invention or active substance combina-VI 55 tions together with a pharmaceutically acceptable carrier. The latter can be an organic or inorganic carrier material suitable for enteral, percutaneous or parenteral administration, such as e.g. water, gum Arabic, lactose, starch, magnesium stearate, tallow, vegetable oils, po-60 lyalkyleneglycols, vaseline and the like. The products can also contain other pharmaceutically active substances, such as antipyrific agents, pain relieving agents, anti-inflammatory agents and the like. The pharmaceutical products can be administered orally, e.g. in the form of tablets, capsules, pills, powders, granules, solutions, syrups, suspensions, elixirs and the like. However, administration can also by effected parenterally, e.g. in the form or sterile solutions, suspensions or emulsions or

DOCKET A L A R M

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

